<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0085077" disease_type="Disease or Syndrome" abbrv="">Sweet's syndrome</z:e> is a <z:e sem="disease" ids="C1142272" disease_type="Disease or Syndrome" abbrv="">neutrophilic dermatosis</z:e> characterized by tender, erythematous, pseudovesicular plaques that can be associated with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancy</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We report a patient with recalcitrant <z:e sem="disease" ids="C0085077" disease_type="Disease or Syndrome" abbrv="">Sweet's syndrome</z:e> that preceded the development of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> by 30 months </plain></SENT>
<SENT sid="2" pm="."><plain>The delay between the <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:e sem="disease" ids="C0085077" disease_type="Disease or Syndrome" abbrv="">Sweet's syndrome</z:e> and the subsequent diagnosis of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> highlights the need for thorough and repeated evaluation for underlying <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> in patients with such a course </plain></SENT>
<SENT sid="3" pm="."><plain>Although <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> are the initial treatment of choice, this patient's eruption was only partially responsive to high-dose <z:chebi fb="0" ids="8382">prednisone</z:chebi> and was refractory to <z:chebi fb="1" ids="6909">metronidazole</z:chebi>, dapsone, and <z:chebi fb="0" ids="44185">methotrexate</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>Treatment with thalidomide resulted in complete resolution of the cutaneous lesions within one month of therapy </plain></SENT>
</text></document>